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Metabotropic glutamate receptor 4 (mGluR4) possesses immune modulatory properties in vivo, such that
a positive allosteric modulator (PAM) of the receptor confers protection on mice with relapsing-remitting
experimental autoimmune encephalomyelitis (RR-EAE). ADX88178 is a newly-developed, one such
mGluR4 modulator with high selectivity, potency, and optimized pharmacokinetics. Here we found that
application of ADX88178 in the RR-EAE model system converted disease into a form of milddyet
chronicdneuroinﬂammation that remained stable for over two months after discontinuing drug treat-
ment. In vitro, ADX88178 modulated the cytokine secretion proﬁle of dendritic cells (DCs), increasing
production of tolerogenic IL-10 and TGF-b. The in vitro effects required activation of a Gi-independent,
alternative signaling pathway that involved phosphatidylinositol-3-kinase (PI3K), Src kinase, and the
signaling activity of indoleamine 2,3-dioxygenase 1 (IDO1). A PI3K inhibitor as well as small interfering
RNA targeting Ido1dbut not pertussis toxin, which affects Gi protein-dependent responsesdabrogated
the tolerogenic effects of ADX88178-conditioned DCs in vivo. Thus our data indicate that, in DCs, highly
selective and potent mGluR4 PAMs such as ADX88178 may activate a Gi-independent, long-lived regu-
latory pathway that could be therapeutically exploited in chronic autoimmune diseases such as multiple
sclerosis.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glutamate (Glu), the major excitatory neurotransmitter in theine 2,3-dioxygenase 1; ITIM,
luR, metabotropic glutamate
hosphatidylinositol-3-kinase;
e encephalomyelitis; Treg, T
.
Ltd. This is an open access article ucentral nervous system (CNS), activates ligand-gated ion channels
(ionotropic) receptors (iGluRs), as well as G-protein coupled
(metabotropic) receptors (mGluRs). mGluRs form a family of eight
subtypes, subdivided into three groups on the basis of their amino
acid sequence, pharmacology, and G-protein coupling. Group I in-
cludes mGluR1 and mGluR5, which are coupled to Gq protein;
group II includes mGluR2 and mGluR3, which are coupled to Gi and
Go proteins; group III includes mGluR4, mGluR6, mGlur7 and
mGluR8, which are also coupled to Gi and Go in heterologous
expression systems (Conn and Pin, 1997).
Much like other neurotransmitters, and owing to the diverse
nature and function of its receptors, Glu might affect immunity via
speciﬁc effects on cells of the immune system (Franco et al., 2007;nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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lacking mGluR4 are remarkably vulnerable to acute experimental
autoimmune encephalomyelitis (EAE), in that they develop exac-
erbated neuroinﬂammatory responses, dominated by IL-
17eproducing T helper type 17 (Th17) cells (Fallarino et al., 2010;
Hansen and Caspi, 2010; Volpi et al., 2012). Moreover, prophylac-
tic but not therapeutic treatment with N-Phenyl-7- (hydroxyimino)
cyclopropa[b]chromen-1a-carboxamide (PHCCC), an mGluR4 pos-
itive allosteric modulator (PAM), protected wild-type (WT) mice
from acute EAE, an effect accompanied by reduced Th17 responses
and increased numbers of CD4þFoxp3þ regulatory T (Treg) cells
inﬁltrating CNS (Fallarino et al., 2010). Moreover, the drug did exert
therapeutic effects, albeit short-lived, in an experimental model of
relapsing-remitting EAE (RR-EAE), which more closely resembles
humanmultiple sclerosis (Fallarino et al., 2010). We also found that
constitutive expression of mGluR4 occurred in all dendritic cell
(DC) subsets and in speciﬁc CD4þ Tcell subtypes, including Treg but
not inﬂammatory Th17 cells. However, the absence of mGluR4 in
DCsdrather than in CD4þ T cellsdwould tip the balance of Th cell
differentiation in favor of the inﬂammatory Th17 phenotype.
Although numerous studies have examined the biological ef-
fects of PHCCC, several major issues with the compound scaffold
still remain opendPHCCC (a) is not very potent and highly selec-
tive, being an mGluR1 antagonist as well; (b) cannot be adminis-
tered by the oral route; and (c) manifests limited brain penetration
ability (Maj et al., 2003; Williams et al., 2010).
In the present study, we investigated the in vivo effects of
ADX88178, a potent, highly selective, orally bioavailable, and brain-
penetrant mGluR4 PAM in the model of RR-EAE as well as its mode
of action in DC cultures. We found that ADX88178 is much more
effective than PHCCC in controlling RR-EAE over the long term and,
more interestingly, it activates an alternative, tolerogenic signaling
in DCs that relies on PI3K, Src, noncanonical NF-kB, and immuno-
regulatory IDO1.
2. Materials & methods
2.1. Animals
Ten-week-old female SJL/J mice (Charles River Breeding labo-
ratories) were used in RR-EAE experiments. For in vitro experi-
ments, 8- to 12-week-old C57BL/6 mice, referred to as WT controls
(purchased from Charles River Breeding laboratories), and Grm4/
mice were used. Speciﬁcally, Grm4þ/ (B6.129-Grm4tm1Hpn/J)
mice, also on a C57/BL6 background, were purchased from The
Jackson Laboratory (Bar Harbor, ME). The Grm4/ offspring of
heterozygoteswas used to establish colonies of Grm4/mice in the
animal facility of the University of Perugia. Although characterized
by altered spatial learning and memory, Grm4/mice do not show
any gross motor abnormalities or alterations of ﬁne motor coordi-
nation (Pekhletski et al., 1996). All mice used in these studies were
genotyped by PCR of DNA isolated from tail clippings. In the skin
test assay, 8- to 12-week-old Balb/c (Charles River Breeding labo-
ratories) were used. RR-EAE Exp. A and skin test assays were in
compliance with national (Italian Approved Animal Welfare
Assurance A-3143-01) and Perugia University Animal Care and Use
Committee guidelines, and the overall study was approved by the
Bioethics Committee of the University of Perugia. RR-EAE Exp. B,
externally performed by MD Biosciences Ltd. (Neurology Discovery
Services Division, Weizmann Science Park, Ness Ziona, Israel), was
conducted in compliance with rules and regulations of the Israel
Committee for Ethical Conduct in the Care and Use of Laboratory
Animals. All animal studies complied with the ARRIVE guidelines,
ensuring that all efforts weremade to minimise animal suffering, to
reduce the number of animals used, and to utilise alternatives toin vivo techniques, if available.
2.2. Drugs
ADX88178 (5-methyl-N-(4-methylpyrimidin-2yl)-4-(1H-pyr-
azol-4-yl)thiazol-2-amine; CAS: 1235318-89-4) (Kalinichev et al.,
2014), ADX104608 (PCT Int. Appl. (2013) WO2013/107862), and
ADX104583 were synthesized at Addex Therapeutics. PHCCC was
purchased from Tocris Bioscience. Both ADX88178 and PHCCC were
formulated in sesame oil for in vivo studies.
2.3. Induction of RR-EAE and in vivo treatments
RR-EAE was induced as described in both Exp. A and Exp. B
(Fallarino et al., 2010). Brieﬂy, SJL/J female mice were immunized
with 100 mg of proteolipid protein peptide 139e151 (PLP139e151;
HSLGKWLGHPDKF) emulsiﬁed in complete Freund adjuvant (CFA;
SigmaeAldrich) with 5 mg/ml Mycobacterium tuberculosis (BD
Difco). Each mouse received s.c. injections of 200 ml emulsion,
fractionated in two distinct sites draining axillary and inguinal
lymph nodes. Pertussis toxin (PTX, 200 ng/mouse; List Biological
Laboratories) was administered i.p. on the day of immunization and
48 h later. Mice were monitored daily blindly by two independent
observers for clinical scores and body weights at least three times
per week up to 80 d (Exp. A) or daily up to 60 d (Exp. B). EAE re-
actions were scored and recorded according to a 0e15 scale, as
described (Weaver et al., 2005). In the scoring based on a 0e15
scale, the ﬁnal score is the sum of the state of the tail and all of the
four limbs. For the tail, a score of 0 reﬂects no signs, 1 represents a
half paralyzed tail, while a score of 2 is given to a mouse with a fully
paralyzed tail. For each of the hind- or fore-limbs, each assessed
separately, 0 signiﬁes no signs, a score of 1 is a weak or altered gait,
2 represents paresis, while a score of 3 denotes a fully paralyzed
limb. Thus, a fully paralyzed quadriplegic animal would attain a
score of 14, whereasmortality equals a score of 15. At the beginning
of the ﬁrst clinical attack (at 10e12 d in both experiments), mice
were randomized into groups to be treated daily for two weeks and
every other day on the third week with either vehicle alone (ses-
ame oil), ADX88178 (at 10e30e60 mg/kg), or PHCCC (3 mg/kg; all
administered s.c.). Dosing solutions in sesame oil (ready-to-
administer) at 10mL/kg were provided with blinded code. A 15-day
stability of dosing solutions was performed and dosing solutions
were stored at 4 C until use. A relapse was deﬁned as a sustained
(2 d) increase in clinical score by at least 1 (or 3 in Exp. B) full
grade after the animal had improved previously by at least 1 (or 3 in
Exp. B) full grade and stabilized for at least 2 d as described (Theien
et al., 2003). Mean peak clinical score was deﬁned as the greatest
clinical score reached during a speciﬁed phase of the treatment (on
treatment or post treatment).
2.4. Collection of sera samples and ADX88178 plasma concentration
analysis
Satellite groups to be used for pharmacokinetic studies were
vaccinated with PLP and treated with either 10 or 60 mg/kg
ADX88178, respectively, as described above. Blood samples were
collected at days 1, 7 and 14 of drug administration by retro-orbital
bleeding to produce approximately 50 ml of plasma on each
bleeding. On each blood sampling day, plasma specimens were
prepared immediately, frozen and shipped to Addex Therapeutics
for analysis. For the dose of 30 mg/kg, plasma samples from naïve
SJL/J mice were used.
For analysis of ADX88178 plasma concentrations, 50 ml of
plasma samples spiked with 10 ml DMSO for unknown samples or
10 ml of ADX88178 for calibration and quality control samples were
C. Volpi et al. / Neuropharmacology 102 (2016) 59e71 61precipitated with 150 mL of acetonitrile. After vortexing and
centrifuging (15 min at 4 C and 13,200 rpm), a sample portion
(100 mL) was transferred into a 384-well analytical plate. Five ml of
the supernatant were injected into an ultra performance liquid
chromatography system (Waters) coupled with mass spectrometry
(API 3200, Applied Biosystems), and signal was detected in an
electrospray ionization positive mode. By using a 0.9 min gradient
from 25% to 100% acetonitrile in formic acid/ammonium formate
buffer at pH 3.5, the retention time of ADX88178 was 0.4 min.
2.5. Leukocyte isolation and Real-Time PCR
Puriﬁcation of leukocytes from spinal cords (SC) were per-
formed as described (Fallarino et al., 2010). Brieﬂy, spinal cords
were recovered from anesthetized mice perfused with cold PBS.
After centrifugation of spinal cord homogenates, inﬁltrating leu-
kocytes were separated on a discontinuous percoll gradient
(SigmaeAldrich).
Real-Time PCR (for Rorc, Foxp3, and Ido1) analyses were carried
out as described (Fallarino et al., 2010; Pallotta et al., 2011) and
expression of each gene was normalized to Gapdh expression, as
determined by the relative quantiﬁcation method (DDCT)
(mean ± SD of triplicate determination).
2.6. In vitro cell stimulation and treatments of puriﬁed DCs
Splenic DCs were puriﬁed by magnetic-activated cell sorting
using CD11c MicroBeads and MidiMacs (Miltenyi Biotec), in the
presence of EDTA to disrupt DC-T cell complexes, as described
(Grohmann et al., 2007; Orabona et al., 2008; Pallotta et al., 2011).
In sorting CD8 DCs, CD11cþ cells were further fractionated using
CD8MicroBeads (Miltenyi Biotec) (Belladonna et al., 2008; Fallarino
et al., 2010; Pallotta et al., 2011). PHCCC, ADX88178, ADX104608,
and ADX104583 were dissolved in DMSO at an initial concentration
of 10 mM and diluted in complete cell culture medium in order to
obtain the desired ﬁnal concentration. DCs were incubated for 24 h
with medium alone (unstimulated cells) or with 1 mg/ml LPS (strain
0:55; SigmaeAldrich). Drugs were added to the cultures 30 min
before LPS, until recovering supernatants at 24 h. In selected ex-
periments, LY294002 (inhibitor of PI3K; Cell Signaling Technology),
PP2 (an Src inhibitor), and PP3 (negative control for the Src inhib-
itor; both from Tocris Bioscience) were also used at the ﬁnal con-
centration of 25 (LY294002) or 5 (PP2 and PP3) mM with the same
timing of PAMs. PTX was added to DC cultures at the ﬁnal con-
centration of 200 ng/ml 2 h before addition of PAMs.
2.7. Cytokine and kynurenine determination
Mouse cytokines (IL-6, IL-10, and TGF-b1) were measured in
culture supernatants by ELISA using speciﬁc kits (eBioscience and
Promega) or previously described reagents (Fallarino et al., 2010;
Pallotta et al., 2011). The functional activity of IDO1 was
measured in vitro in terms of the ability to metabolize tryptophan
to L-kynurenine, whose concentration was measured by high-
performance liquid chromatography in culture supernatants at
16 h after the addition of 100 mM tryptophan for the ﬁnal 8 h
(Grohmann et al., 2002, 2007).
2.8. cAMP determination
Measurements of intracellular cAMP levels were performed
essentially as described (Fallarino et al., 2010) with some modiﬁ-
cations. Brieﬂy, DCs (0.5  106 cells/150 ml/sample) were pre-
incubated in Locke's solution buffer (glutamate-free), pH 7.4, con-
taining 0.5 mM isobutylmethylxanthine (a phosphodiesteraseinhibitor) for 20 min to block the breakdown of cAMP. PHCCC and
ADX compounds (dissolved in DMSO at the initial concentration of
10 mM and diluted in Locke's solution at different ﬁnal concen-
trations) were added 30 s before the addition of 10 mM forskolin
(SigmaeAldrich) and the incubation was continued for additional
10 min. The reaction was stopped by incubating samples for 2 min
on ice. Samples were then centrifuged at 5000 rpm for 5 min at
4 C, washed in PBS, and intracellular cAMP levels were measured
using the Direct Cyclic AMP enzyme immunoassay kit (Arbor
Assays).
2.9. Western blotting
IDO1 and pIDO1 expressions were investigated in DCs by
immunoblot with a rabbit monoclonal anti-mouse IDO1 antibody
(cv152) or a rabbit polyclonal antibody to the phosphorylated ITIM2
motif of IDO1, respectively, both raised in our laboratory (Pallotta
et al., 2011). Src and its phosphorylated form were revealed by
speciﬁc anti-Src and -pSrc antibodies (Tyr416; Cell Signaling
Technology). Anti-Akt and epAkt were also from Cell Signaling
Technology. Antieb-actin antibody (SigmaeAldrich) was used as a
normalizer.
2.10. Skin test assay
A skin test assay was used for measuring major histocompati-
bility complex class Ierestricted delayed-type hypersensitivity in
response to challenge in the footpad with the IGRP synthetic pep-
tide, as described (Grohmann et al., 2003a; Pallotta et al., 2014),
using 12-wk-old Balb/c as DC donors and recipients. The H-2Kd-
restricted IGRP peptide (KYNKANAFL) is a diabetogenic autoantigen
in nonobese diabetic mice but is also recognized by H-
2dexpressing BALB/c animals (Pallotta et al., 2011). The response
to challenge in the footpad with the eliciting peptide was measured
at 2 wk, and results are presented as the weight of peptide-injected
footpad relative to vehicle-injected counterpart (Grohmann et al.,
2003a, 2002, 2007; Pallotta et al., 2011; Volpi et al., 2013).
2.11. Statistical analyses
2.11.1. Many-to-one comparisons in repeated measures one-way
ANOVA design
To assess whether treatment with ADX88178 and with PHCCC
was effective in reducing disease severity as compared to vehicle
treatment, we contrasted each treatment groupwith the respective
controldPHCCC vs. vehicle, 10 mg/kg ADX88178 vs. vehicle, 30 mg/
kg ADX88178 vs. vehicle and 60 mg/kg ADX88178 vs. vehicle
(Table S2). An additional analysis was performed by comparing the
PHCCC-treated group vs. ADX88178-treated groups (Table S3).
Mean group EAE severity scores with standard errors are displayed
in Fig. 2A. For each comparison, a two-sample Wilcoxon-Mann-
Whitney one-sided test was performed at each measurement time.
Global signiﬁcance over time was obtained by using the maxT
permutation-based familywise error rate controlling method of
Westfall & Young (Goeman and Solari, 2014) to account for within
experimental unit correlation existing in longitudinal data and for
multiple time points. Finally, global P-values were multiplicity-
adjusted for the four comparisons by using the Bonferroni-Holm
method (Goeman and Solari, 2014).
2.11.2. Other analyses
Unpaired Student's t-test was used for in vitro analyses, using at
least three values from 1 to 3 experiment per group, and for the
skin test assay (using at least 6 mice per group). For cell recovery,
one way ANOVA associated with Bonferroni's analysis between
Fig. 2. ADX88178 exerts long-term, therapeutics effects in RR-EAE. RR-EAE was
induced in SJL/J mice by immunization with the PLP peptide on day 0. Two separated
experiments, conducted as described in Materials and Methods, led to similar results.
Mice were treated s.c. daily for 2 wk and every other day for an additional wk (indi-
cated) with vehicle (control), PHCCC at 3 mg/kg or ADX88178 at 10, 30, or 60 mg/kg,
starting from the disease onset. (A) Mean clinical scores over time. Grey boxes in-
dicates the drug treatment period. Indicated P-values represent the global P-values
(see also Table S3). (B) Clinical score mean differences over the time period encom-
passing (on treatment; day 0 corresponding to day 10 post-PLP sensitization) or after
drug treatment (post treatment; day 0 corresponding to day 31 post-PLP sensitization).
Indicated P-values represent the global P-values for each group in each deﬁned time
period. Blue bars (P > 0.05), yellow bars (P < 0.05), and red bars (P < 0.01). (C) Foxp3
and Rorc transcript levels in leukocytes puriﬁed from spinal cords of mice used in Exp.
A at 60 d by Real Time-PCR, using Gapdh expression for normalization. Data are pre-
sented as fold change in normalized transcript expression in RR-EAE mice relative to
vehicle-injected counterparts (in which fold change ¼ 1; dotted line). All data (AeC)
are presented as means ± SE. *P < 0.05.
Fig. 1. Chemical structures of mGluR4 PAMs evaluated in the mouse RR-EAE model.
PHCCC (N-Phenyl-7- (hydroxyimino)cyclopropa[b]chromen-1a-carboxamide) and
ADX88178 (5-methyl-N-(4-methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)thiazol-2-amine).
C. Volpi et al. / Neuropharmacology 102 (2016) 59e7162speciﬁc pairs of samples was used. Differences were considered
signiﬁcant with P < 0.05.
3. Results
3.1. ADX88178 exerts long-term therapeutic effects in RR-EAE
Our previous studies indicated that PHCCC signiﬁcantly reduces
the number and severity of relapses in mouse RR-EAE, but only if
continuously administered s.c. until the end of the experiment
(daily dose of 3 mg/kg) (Fallarino et al., 2010). We here compared
the efﬁcacy of a short administration regimen of the previously
used dose of PHCCC and ADX88178 (the most potent and selective
mGluR4 PAM as revealed by pharmacological analyses; SI Results)
at the dose of 10, 30, and 60 mg/kg in the same disease setting
(Figs. 1 and 2). Either drug was administered s.c. daily for the ﬁrst
two weeks and every other day for the third week, starting
approximately at 10 days post vaccination (i.e., at the ﬁrst clinical
attack) with the proteolipid protein peptide (PLP), and clinical
scores were measured daily up to 60 days, when mice were sacri-
ﬁced. For pharmacokinetic analyses, satellite groups of mice were
administered ADX88178 at either 10 or 60 mg/kg and blood sam-
ples collected at days 1, 7 and 14 of drug administration. The
administration of ADX88178 at the dose of 60 but not 10 mg/kg
maintained a total plasma concentration close to, or greater than,
55 ng/ml (Table S1), that is, above the minimal effective concen-
tration (9 nM) in vitro that ensues potentiation of mGluR4 activa-
tion (Kalinichev et al., 2014).
Analysis of the disease proﬁle over the entire duration of the
experiment indicated that all animal groups exhibited approxi-
mately two episodes (or three, for mice receiving the lowest dose of
ADX88178) of RR-EAE followed by a chronic phase of the disease
(Fig. 2A). The overall drug effect in each experimental group was
evaluated by determining the global signiﬁcance (i.e., global P
value) of daily mean clinical scores over the entire period of
observation (from day 10 to day 60 of post-sensitization with PLP)
on contrasting drug vs. vehicle administration by a robust statistical
analysis as described in Material and Methods. Mice on PHCCC or
ADX88178 at 10 mg/kg did not reach the global signiﬁcance
threshold when compared to the vehicle group (Fig. 2A and
Table S2; global P¼ 0.1763 and 0.4513, respectively). In contrast, the
global therapeutic effect over time of ADX88178 at the doses of 30
and 60 mg/kg was almost (P ¼ 0.0853) or highly signiﬁcant
(P ¼ 0.0095), respectively (Fig. 2A and Table S2).
To evaluate whether the global analysis could have masked
signiﬁcant therapeutic effects occurring during or after drug
treatment, the statistical analysis was re-run on speciﬁc time
frames, i.e., on treatment (including the three weeks of drug
treatment) and post treatment (after day 31 of post-sensitization
with PLP). On comparing the clinical score mean differences of
drug v. vehicle administration at such speciﬁc periods of time, we
found that, again, treatment with either PHCCC or ADX88178 at the
C. Volpi et al. / Neuropharmacology 102 (2016) 59e71 63lowest dose did not reach the global signiﬁcance value during or
after drug treatment, although signiﬁcant differences (P < 0.05)
with the vehicle group could be observed for PHCCC treatment at
two early time points (Fig. 2B and Table S2). In contrast, the highest
dose of the selective PAM did yield global signiﬁcance effects dur-
ing the entire timeframe of treatment (P ¼ 0.0058). The same dose
during the post-treatment period and the median dose during both
time periods yielded results very close to global signiﬁcance
(P ¼ 0.0691 and P ¼ 0.0868, respectively). Moreover, in theFig. 3. ADX88178 and ADX104608 increase the production of IL-10 and TGF-b in mGluR4-ex
puriﬁed from the spleens of C57BL/6 mice were either left unstimulated or stimulated with
ADX88178 and ADX104608. PHCCC and the negative control (ADX104583), both at 30 mM, we
TGF-b production by DCs treated with mGluR4 PAMs. DCs from WT or Grm4/ C57BL/6 m
different concentrations (WT mice) or 3 mM (Grm4/ mice) of ADX88178 and ADX104608
natants were harvested and assayed for cytokine contents by ELISA. All data (A, B), presented
three. *P < 0.05 and **P < 0.01 (drug-treated samples vs control).ADX88178 at 30 and 60 mg/kg groups, mean clinical scores were
signiﬁcantly different (P < 0.05 and P < 0.01) from those of the
vehicle group at several, speciﬁc time points, at either on or post
treatment times (Fig. 2B). No signiﬁcant effects could be observed
for any treatments on mean body weights (Fig. S1) as compared to
the control group.
To get some insight into the immunoregulatory effects possibly
exerted by the two mGluR4 PAMs in RR-EAE, mice were sacriﬁced
at the end of the experiment to evaluate histopathology and naturepressing DCs. (A) Viability of splenic DCs treated with ADX compounds. DCs (106/well)
LPS in the presence or absence (Ctrl, control) of different concentrations (indicated) of
re also used. After 24-h of culture, cells were harvested and counted. (B) IL-6, IL-10, and
ice were either left unstimulated or stimulated with LPS in the presence or absence of
. PHCCC and ADX104583 were also assayed as in (A). After 24 h of culture, cell super-
as means ± SD from triplicate samples, are shown for one representative experiment of
C. Volpi et al. / Neuropharmacology 102 (2016) 59e7164of inﬁltrating lymphocytes in spinal cords. In line with previous
results by others in the mouse RR-EAE model (Theien et al., 2003),
low-grade inﬂammation and limited damage of myelin-containing
nervous ﬁbers could be detected in all groups, with some im-
provements in mice given ADX88178 at 30 and 60 but not 10mg/kg
as well as PHCCC (Fig. S2). On performing Real-Time PCR experi-
ments, we found a signiﬁcant increase in the expression of Foxp3
(encoding the Treg speciﬁcation factor) in transcripts of inﬁltrating
leukocytes puriﬁed from the spinal cords of PHCCC- or ADX88178-
treatedmice as compared to control animals (Fig. 2C). Interestingly,
the increase in Foxp3 expression was signiﬁcantly higher in
ADX88178-treated (at 30 and 60 mg/kg) than PHCCC-treated mice.
Moreover, Rorc transcripts (encoding the Th17 speciﬁcation factor)
were signiﬁcantly downregulated in ADX88178-but not PHCCC-
treated animals.
Overall, our data, besides further conﬁrming the therapeutic
value of mGluR4 PAMs in neuroinﬂammation, indicate that
ADX88178, possibly by virtue of its stringent mGluR4 selectivity,
high potency and optimal bioavailability, exhibits higher efﬁcacy in
RR-EAE than PHCCC (Table S3). Perhaps more importantly, the
therapeutic effects of ADX88178dat variance with PHCCC
(Fallarino et al., 2010)dcould be still observed after drug discon-
tinuation, albeit to a lower extent, as suggested by a reduced sig-
niﬁcance level (P ¼ 0.0691; Fig. 2 and Table S2), and its
disappearance from plasma (Table S1), suggesting the involvement
of mechanisms that, once activated, are capable of self-sustaining
immunoregulatory effects over the long term.
3.2. ADX88178 and ADX104608 induce an immunoregulatory
cytokine proﬁle in DCs in an mGluR4-dependent fashion
Our previous studies indicated that the immunoregulatory ef-
fects of mGluR4 activation are wholly dependent on DCs. In fact, in
DC-T cell co-cultures, the absence of Grm4 (the gene coding for the
receptor) in DCs but not in CD4þ T cells favored the emergence of
Th17 cells (Fallarino et al., 2010). In cultures with DCs alone acti-
vated with the TLR4 agonist LPS, lack of mGluR4 increased the
production of IL-6 and IL-23 (both cytokines being required for the
induction and/or expansion of Th17 cells) and of IL-10 as well, and it
decreased the levels of secreted IL-12 (the primary stimulus for Th1
cell induction) and of immunoregulatory TGF-b. Conversely, in vitro
treatment of WT DCs with PHCCC reduced the production of IL-6,
IL-10 and IL-23, and it increased IL-12 and TGF-b, but only when
cells had been activated with LPS. As a whole, our previous studies
suggested that, under inﬂammatory conditions, PHCCC can signif-
icantly bias the cytokine secretion proﬁle of DCs towards a less
proinﬂammatory and more immunoregulatory proﬁle, although
the reduction in IL-10, a typically anti-inﬂammatory mediator
(Saraiva and O'Garra, 2010), would not ﬁt properly into such a
conceptual framework.
Because DCs are non-proliferating cells and several maneuvers,
including drug treatments, are known to decrease their viability
in vitro (Hackstein and Thomson, 2004), we ﬁrst evaluated whether
ADX88178 and the novel mGlu4R PAM ADX104608 (SI Results)
would affect viability in DCs. We measured cell viability in terms of
absolute number of cells recovered after a 24-h culture of puriﬁed
conventional DCs, i.e., expressing the DC marker CD11c, with or
without mGluR4 PAMs at different concentrations (30 nMe30 mM),
in the presence or absence of LPS. PHCCC and ADX104583 (inactive
at mGluR4) were also assayed (both at 30 mM). No signiﬁcant effects
on the recovery of DCs after a 24-h culture could be observed for all
of the tested compounds (Fig. 3A). Thus these data suggest that
selective mGluR4 PAMs will not signiﬁcantly affect cell viability in
DCs.
We then evaluated the in vitro effects of ADX88178 andADX104608 at different concentrations on the production of IL-6,
IL-10, and TGF-b1 by DCs, either unstimulated or stimulated with
LPS. PHCCC and ADX104583 at 30 mM were used as controls. In
accordance with our previous data, PHCCC signiﬁcantly reduced
production of IL-6 and IL-10 and increased the production of TGF-
b1 in DCs activated by LPS but not in unstimulated cells (Fig. 3B).
Although no change could be observed in the levels of proin-
ﬂammatory IL-6, ADX88178 and ADX104608 signiﬁcantly increased
production of all the anti-inﬂammatory cytokines being tested,
namely TGF-b1 and IL-10 as well, an effect that was evident in both
LPS-activated and non-activated DCs (Fig. 3B). No signiﬁcant
modulatory effect was found in the production of any cytokine
upon treatment with the negative control compound. All cytokines
found to be modulated signiﬁcantly by mGluR4 PAMs were also
measured in culture supernatants from DCs puriﬁed from the
spleens of Grm4/ mice, using the same drug concentrations as
above, but no signiﬁcant modulations were found (Fig. 3B).
These data indicate that selective and potentmGluR4 PAMs such
as ADX88178 and ADX104608 exert important effects on DCs,
promoting a clear immunoregulatory cytokine proﬁle that, how-
ever, is distinct from that induced by PHCCC. Thus ADX88178 and
ADX104608 may have a differentdyet mGluR4-dependentdmode
of action, as compared to PHCCC.
3.3. Selective mGluR4 PAMs activate Gi-dependent and
-independent signaling pathways in DCs
In presynaptic nerve terminals and microglia, mGluR4 activa-
tion lowers intracellular cAMP formation in a Gi protein-dependent
fashion (Conn and Pin, 1997). In our previous work (Fallarino et al.,
2010), we demonstrated that PHCCC reduces formation of cAMP in
DCs stimulated with forskolin, a direct activator of adenylyl cyclase.
We therefore measured cAMP levels in DCs stimulated with for-
skolin in the presence or absence of ADX88178 or ADX104608 at
different concentrations. PHCCC and ADX104583 were used as a
positive and negative control, respectively. In accordance with our
previous data, PHCCC at 3 and 30 mM signiﬁcantly reduced the
cAMP formation in DCs. ADX88178 and ADX104608 also reduced
cAMP levels as induced by forskolin in DCs, but only when used at
the highest concentration, i.e., 30 mM (Fig. 4A).
Because the in vitro effects of selective mGluR4 PAMs on the
production of immunoregulatory cytokines by DCs were observable
at 3 mM (and also at 0.3 mM; Fig. 3B) and no modulation of cAMP
levels was evident at this concentration, we asked whether
ADX88178 and ADX104608 effects could be, at least at low con-
centrations, Gi-independent. To verify our hypothesis, TGF-b and IL-
10 levels were measured in culture supernatants of DCs pre-
incubated for 2 h with pertussis toxin (PTX), a standard investiga-
tive tool that uncouples metabotropic receptors fromGi/Go proteins
(Kurose and Ui, 1983), prior to the 24 h-incubation with mGluR4
PAMs in the presence or absence of LPS. Pre-incubation with PTX
signiﬁcantly decreased and increased the levels of IL-10 and TGF-b,
respectively, induced by PHCCC in LPS-stimulated cells (Fig. 4B). In
contrast, upregulation of TGF-b and IL-10 as induced by ADX88178
and ADX104608 in either unstimulated or LPS-stimulated DCs were
not signiﬁcantly affected by PTX (Fig. 4C). Although PTX alone
upregulated TGF-b and IL-10 in LPS-treated DCs (Fig. 4B,C), an effect
previously reported as being due to toxin synergism with TLR4
signaling (Nishida et al., 2010), these data seemed to suggest that
the immunoregulatory effects of selective mGluR4 PAMs in DCs are
Gi-independent.
G-protein activation is considered to be a key event in mGluR-
dependent responses. Nevertheless, alternative pathways can also
be at work (Enz, 2007; Gerber et al., 2007). In particular, stimulation
of group III mGluRs by L-AP-4, a nonselective orthosteric agonist,
Fig. 4. PI3K/Akt- and Src- but not Gi-dependent signaling pathways are required for the production of IL-10 and TGF-b by DCs treated with ADX88178 and ADX104608. (A)
Intracellular cAMP formation in DCs treated with mGluR4 PAMs. Cells were stimulated with forskolin (or left unstimulated as control) at 10 mM for 10 min in the presence or absence
of ADX88178, ADX104608, and PHCCC at different concentrations. Ctrl, control. (B) Effect of PTX on the inhibition of IL-10 and induction of TGF-b by PHCCC in LPS-stimulated DCs.
DCs treated with PHCCC at 30 mM were stimulated with LPS in the presence or absence of PTX at different concentrations and cytokine contents were measured in 24-h culture
supernatants. (C) Effect of PTX on the induction of IL-10 and TGF-b by ADX88178 and ADX104608. DCs treated with ADX88178 or ADX104608 at 3 mM were left unstimulated or
stimulated with LPS in the presence or absence of PTX at 0.2 mM and cytokine contents were measured in 24-h culture supernatants. (D) Kinetics of Akt and Src phosphorylation in
WT DCs treated with ADX88178 at 3 mM. Lysates from drug-treated DCs (not subjected to LPS stimulation) were analyzed by sequential immunoblotting with antibody to
phosphorylated Akt (pAkt) and anti-Akt or to phosphorylated Src (pSrc) and anti-Src. (E) Kinetics of Src phosphorylation in Grm4/ DCs treated as in D. (F) Effect of PI3K (LY294002;
25 mM) and Src (PP2; 5 mM) inhibitors on the induction of IL-10 and TGF-b by ADX88178 and ADX104608 in WT DCs. PP3 (5 mM) was used as PP2 negative control. DCs (not subjected
to LPS stimulation) were treated with selective mGluR4 PAMs at 3 mM in the presence or absence of enzyme inhibitors and cytokine contents were measured in 24-h culture
supernatants. Data (A-C and F), presented as means ± SD from triplicate samples, are shown for one representative experiment of three. In D and E, one experiment of two. *P < 0.05,
**P < 0.01, and ***P < 0.001.
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neurons (Jiang et al., 2006). Moreover, in cerebellar granule cells,
group III mGluRs are functionally coupled to the PI3K/Akt pathway,
which is required for the neuroprotective effects of L-AP-4 (Iacovelli
et al., 2002).
We therefore investigated whether ADX88178 and ADX104608,
at concentrations reﬂecting functional effects in DCs, could activate
a signaling pathwaymediated by PI3K/Akt and/or Src kinase in DCs.
Phosphorylation of Akt and Src was evaluated by immunoblottingin DC lysates from WT mice and incubated with mGluR4 PAMs for
5e60 min in the absence of TLR4 activation (Fig. 4D). Akt and Src
phosphorylation occurred at 15 min of treatment of WT DCs with
ADX88178 at 3 mM and remained at sustained levels up to 1 h
(Fig. 4D). In contrast, no phosphorylation of Src could be detected in
Grm4/ DCs at any time points (Fig. 4E). Although similar results
were obtained with ADX104608, PHCCC did not induce Akt and Src
phosphorylation in DCs (data not shown).
TGF-b and IL-10 levels were next measured in culture
Fig. 5. ADX88178 and ADX104608 induce IDO1 expression and activate IDO1 signaling in DCs. (A) Expression of Ido1 transcripts in DCs treated with mGluR4 PAMs. WT DCs were
treated with ADX88178 or ADX104608 at 3 mM, or PHCCC at 30 mM, for 24 h and analyzed for Ido1 expression by Real-Time PCR, using expression of the Gapdh gene for
normalization. Data are presented as normalized transcript expression in the samples relative to normalized transcript expression in the control (i.e., untreated DCs) culture (that is,
fold change ¼ 1, dotted line). (B) Expression of the IDO1 protein in WT DCs treated with mGluR4 PAMs. Cell lysates from DCs treated as in A for 24 h were subjected to sequential
immunoblotting analysis by using speciﬁc antieIDO1 and eb-actin antibodies. (C) IDO1 catalytic activity in WT and Grm4/ DCs treated with mGluR4 PAMs and modulation thereof
by PTX or PI3K and Src inhibitors. DCs were treated as in (B) and IDO1 catalytic activity was assessed as L-kynurenine in culture supernatants. (D) Kinetics of phosphorylation of
IDO1 ITIM in WT DCs treated with ADX88178. DC cell lysates were analyzed by sequential immunoblotting with antiepIDO1, eIDO1, and eb-actin speciﬁc antibodies. (E) Activation
of p65, p52 and RelB in nuclear extracts of WT DCs treated or untreated (time 0) with ADX88178 at 3 mM for different times measured by ELISA. Results are presented as absorbance
at 450 nm (A450). One representative experiment out of two (D, E) or three (AeC) is shown. Data (A, C, and E) are presented as means ± SD from triplicate samples. *P < 0.05,
**P < 0.01, and **P < 0.001.
C. Volpi et al. / Neuropharmacology 102 (2016) 59e7166supernatants of DCs treated with the selective mGluR4 PAMs for
24 h after preincubation with LY294002 (a PI3K inhibitor) or PP2 (a
Src inhibitor) for 2 h. PP3 was used as a PP2 negative control. The
PI3K inhibitor completely ablated both TGF-b and IL-10 induction
by ADX88178 and ADX104608, whereas inhibition by the Src
antagonist was only partial (Fig. 4F). No signiﬁcant effects could be
observed for PP3.
Overall, these data indicated that, as previously reported for
other metabotropic receptors (Jones et al., 1991), different con-
centrations of mGluR4 ligands can activate distinct mechanisms,
i.e., Gi-dependent and -independent in nature. Perhaps most
importantly, a PI3K/Src-rather than Gi-mediated signaling pathway
appears to be indispensable for the immunoregulatory efﬁcacy of
ADX88178 and ADX104608 in DCs.
3.4. Selective mGluR4 PAMs induce IDO1 expression and signaling
in DCs
Indoleamine 2,3-dioxygenase 1 (IDO1) is a natural immuno-
regulatory mechanism that contributes to immune suppression
and tolerance in a variety of settings (Grohmann et al., 2003b;
Mellor and Munn, 2004). IDO1 immunoregulatory effects are
mainly mediated by DCs and involve tryptophan deprivation and
production of immunoactive kynurenines. As a result, IDO1-
expressing DCs mediate multiple effects on T lymphocytes,including inhibition of proliferation, apoptosis, and differentiation
towards a regulatory phenotype (Grohmann and Bronte, 2010;
Puccetti and Grohmann, 2007). IDO1-dependent effects also
include non-enzymic functions, namely intracellular signaling
events that, initiated by phosphorylation of speciﬁc domains (i.e.,
immunoreceptor tyrosine-based inhibitory motifs or ITIMs) in the
enzyme, are involved in reprogramming gene expression and in the
induction of a stably regulatory phenotype in splenic DCs (Orabona
et al., 2012; Pallotta et al., 2011). In particular, IDO1 ITIM phos-
phorylation is triggered in DCs by TGF-b, via a pathway that re-
quires PI3K and a tyrosine kinase of the Src family (speciﬁcally, Fyn
in plasmacytoid DCs (Pallotta et al., 2011) or Src in conventional DCs
(Bessede et al., 2014)) that phosphorylates IDO1 ITIMs, thus
creating docking sites for protein phosphatases such as SHP-1 and
SHP-2. These events lead to the activation of an immunoregulatory
signaling pathway in DCs that relies on the noncanonical NF-kB
pathway, endogenous production of TGF-b, and induction of the
Ido1 gene, perpetuating the IDO1 signaling events and the conse-
quent immunosuppressive effects over the long term (Bessede
et al., 2014; Pallotta et al., 2014, 2011).
Considering that ADX88178 exerts long-term immunosuppres-
sive effects in the RR-EAE model (Fig. 2) and, similarly to
ADX104608, induces the production of TGF-b as well as IL-10 by
conventional DCs via a pathway mediated by PI3K and Src (Fig. 4),
we investigated whether selective mGluR4 PAMs could also induce
Fig. 6. Immunoregulatory effects of ADX88178 in DCs are mediated by IDO1 expres-
sion and signaling. (A) Effect of lack of IDO1 expression and signaling in the induction
of IL-10 and TGF-b by ADX88178 in DCs. WT and Ido1/ DCs were treated with
ADX88178 at 3 mM and cytokine contents were measured in 24-h culture supernatants.
WT DCs were used as such or after transfection with Ido1, Chuk, Ikbkb, or negative
control (NC) siRNA. Data, presented as means ± SD from triplicate samples, are shown
for one representative experiment of three. *P < 0.01. (B) Effect of lack of IDO1
expression and signaling in the in vivo suppressive ability of ADX88178-conditioned
DCs. Puriﬁed CD8eCD11cþ DCs were pulsed for 2 h with the IGRP peptide and trans-
ferred into recipient mice to be assayed for skin reactivity to the eliciting peptide. The
CD8eCD11cþ DC fraction was used in combination with 5% CD11cþ DCs, either un-
treated or preconditioned in vitrowith ADX88178 in the presence or absence of PTX or
LY294002 (LY) as in Fig. 4F. Cells were left untransfected or transfected with siRNA as in
A. Analysis of skin reactivity of recipient mice to the eliciting peptide at 15 d is pre-
sented as change in footpad weight. Results (mean ± SD) are representative of three
experiments. *P < 0.05 and **P < 0.01.
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with ADX88178 or ADX104608 at 3 mM or PHCCC at 30 mM and,
after 24 h, IDO1 expression in terms of both transcript (Fig. 5A) and
protein (Fig. 5B) was evaluated by means of Real-Time PCR and
Western blot analysis, respectively. No evident increase in IDO1
transcripts or protein could be observed in DCs incubated with
PHCCC. In contrast, signiﬁcant up-regulation of Ido1 transcription
and IDO1 protein expression was detected in cells treated with
either ADX88178 or ADX104608 (Fig. 5A,B). Similar results were
obtained on evaluating the levels of L-kynurenine, themain product
of IDO1's catalytic activity, which signiﬁcantly increased in culture
supernatants of WT but not Grm4/ DCs treated with mGluR4PAMs, an effect completely (LY294002), partially (PP2), or not at all
(PTX) (data not shown for PP3) negated by the inhibitors (Fig. 5C).
To investigate whether IDO1 signaling, in addition to IDO1
expression and catalytic activity, could also be induced by selective
mGluR4 PAMs, we evaluated IDO1 phosphorylation, using an
antibody speciﬁc for the phosphorylated form of the enzyme
(pIDO1) (Pallotta et al., 2011). We also investigated the activation of
noncanonical NF-kB in response to DC stimulation with ADX88178.
In fact, molecular dissection of NF-kB activation has shown that NF-
kB can be induced by the so-called canonical (classical; IkB (IKK)b-
dependent) and noncanonical (alternative; IKKa-dependent)
signaling pathways, leading to distinct patterns in the individual
NF-kB subunits that are activated and distinct downstream genetic
responses. While the canonical NF-kB pathway involves the nuclear
translocation of p50-p65 dimers and proinﬂammatory effects, the
noncanonical NF-kB signaling relies on the proteasomal degrada-
tion of p100 into p52 and formation of p52-RelB dimers that
translocate to the nucleus and activate an anti-inﬂammatory gene
program (Bonizzi and Karin, 2004; Puccetti and Grohmann, 2007).
Particularly relevant in this context is the fact that IDO1 expression
and signaling are contingent on activation of the noncanonical NF-
kB pathway (Bessede et al., 2014; Manches et al., 2012; Pallotta
et al., 2014, 2011; Puccetti and Grohmann, 2007; Volpi et al.,
2013). DC treatment with ADX88178 (Fig. 5D) but not PHCCC
(data not shown) induced the appearance of pIDO1 at 30e60min of
drug incubation. Moreover, the selective mGluR4 PAM (Fig. 5E) but
not PHCCC (data not shown) signiﬁcantly increased the nuclear
translocation of p52 and RelB but not p65 NF-kB subunits, which
peaked at 10 min of drug exposure.
Overall, our data indicated that selective and potent mGluR4
PAMs can be considered as novel inducers of the expression, cat-
alytic activity, and signaling ability as well of immunoregulatory
IDO1 via a mechanism that requires mGluR4, PI3K, Src, and non-
canonical NF-kB but not Gi/Go proteins.
3.5. Selective mGluR4 PAMs induce an IDO1-dependent, tolerogenic
phenotype in DCs
Because ADX88178 and ADX104608 but not PHCCC induce
expression and signaling activity of immunoregulatory IDO1, we
evaluated the possible role of IDO1 in the in vitro and in vivo reg-
ulatory effects induced by selective mGluR4 PAMs in DCs. We used
DCs lacking Ido1 expression either as a consequence of gene knock-
out (i.e., Ido1/ cells) or knock-in maneuvers (cells treated with
Ido1-speciﬁc small interfering RNA; siRNA). Moreover, to evaluate
the possible functional role of the noncanonical versus canonical
NF-kB pathway, siRNAs speciﬁc for Chuk (the IKKa-encoding gene)
or Ikbkb (the IKKb-encoding gene) were also used, respectively. In
the in vitro setting, IL-10 and TGF-b levels weremeasured in culture
supernatants of Ido1/ and WT DCs, the latter after gene silencing
with an Ido1-, Chuk-, Ikbkb-speciﬁc or control siRNA (Pallotta et al.,
2014, 2011) prior to incubation with ADX88178 for 24 h. Induction
of both cytokines by the mGluR4 PAM was severely impaired in
Ido1/cells (or however reduced in Ido1 siRNA-transfected cells)
(Pallotta et al., 2014, 2011), as compared to DCs competent for the
enzyme (Fig. 6A). Moreover, Chuk-speciﬁc siRNA also greatly and
signiﬁcantly inhibited the production of IL-10 and TGF-b, whereas
nomodulatory effect was exerted by either Ikbkb-speciﬁc or control
siRNAs (Fig. 6A).
To better appreciate the tolerogenic potential of DCs treated
with selective mGluR4 PAMs, we resorted to the skin test assay, an
established protocol for measuring the in vivo induction of antigen-
speciﬁc immunoreactivity versus tolerance by DCs (Grohmann
et al., 2007; Orabona et al., 2004; Volpi et al., 2013). Balb/c mice
were sensitized with the IGRP peptide (containing the
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also prime nondiabetic conventional mice such as Balb/c animals
(Pallotta et al., 2014)) (Pallotta et al., 2011) presented by highly
immunostimulatory conventional DCs characterized by the
absence of the CD8amarker (i.e., CD8CD11cþ DCs) in combination
with a minority fraction (approximately 5% of the entire popula-
tion) of the same cells that had been pretreated in vitro with
ADX88178 or medium alone for 24 h and pulsed with the same Ag.
After priming the mice, we assessed immune reactivity at 2 wk by
intrafootpad challengewith the IGRP peptide in the absence of DCs.
As expected, the priming ability of CD8 DCs was not affected by
the presence of untreated cells, yet sensitization together with
ADX88178-pretreated DCs caused suppression of IGRP-speciﬁc
reactivity, an effect abrogated by co-treatment of DCs with the
PI3K inhibitor but not PTX (Fig. 6B). Moreover, the suppressive ef-
fect exerted by ADX88178-pretreated DCs on the sensitization by
IGRP-pulsed CD8 DCs was also lost when cells had been pre-
incubated with Ido1 or Chuk but not Ikbkb or control siRNA prior
to conditioning with the mGluR4 PAM (Fig. 6B).
Therefore, our data suggest that the immunoregulatory effects
of selective mGluR4 PAMs rely on IDO1 but not Gi signaling in DCs
and could be exploited therapeutically in several chronic autoim-
mune diseases, including MS and type 1 diabetes (T1D).
4. Discussion
MS is a disease both inﬂammatory and autoimmune in nature
(McFarland and Martin, 2007; Steinman et al., 2002). IDO1, by
virtue of its anti-inﬂammatory and immunoregulatory effects,
could thus represent a unique therapeutic target in inﬂammatory/
autoimmune diseases such as MS. Interestingly, the reduced
relapse rate of MS observed during pregnancy has been proposed to
be due to the up-regulation of IDO1 by estrogens in monocyte-
derived DCs (Zhu et al., 2007). Moreover, in vitro stimulation of
monocyte-derived DCs from MS patients with 1,25(OH)2D3, the
biologically active form of vitamin D, greatly upregulates expres-
sion and activity of IDO1, an effect that results in increased numbers
of Treg cells in DC-T cell cocultures (Correale et al., 2009). Intrigu-
ingly, kynurenine levels are signiﬁcantly increased in the plasma of
patients undergoing effective therapy with IFN-b, a standard
treatment for MS (Amirkhani et al., 2005).
Tryptophan metabolism by IDO1 in DCs is a highly versatile
regulator of innate and adaptive immune responses (Grohmann
et al., 2003b; Orabona et al., 2012; Puccetti and Grohmann,
2007). When induced by proinﬂammatory cytokines such as IFN-
g, the IDO1 enzyme degrades tryptophan and yields a series of
catabolites (Grohmann et al., 2000, 2002)dcollectively known as
kynureninesdregulating immune homeostasis by acting as ligands
of the aryl hydrocarbon receptor (AhR) and allowing the generation
of Treg cells that protect from hyperinﬂammatory responses
(Bessede et al., 2014; Romani et al., 2008). IDO1 does not merely
degrade tryptophan and produce immunoregulatory kynurenines
but also acts as a signal-transducing molecule independently of its
enzyme activity (Orabona et al., 2012). This additional function is
induced in DCs by TGF-b, is mediated by PI3K, and culminates in
IDO1 phosphorylation by kinases belonging to the Src family.
Because AhReassociated Src activity has recently been found to be
responsible for IDO1 phosphorylation and TGF-b production by
IDO1-competent cells in endotoxin tolerance (Bessede et al., 2014),
the concomitant activation of enzymatic and signaling activities
appears to be mandatory for the implementation of IDO1's
immunoregulatory potential.
Direct evidence for a protective role of IDO1 in MS has been
obtained in mice with different forms of EAE, i.e., acute, relapsing-
remitting, or adoptively transferred disease. Administration of 1-MT, the standard inhibitor of IDO1 catalytic activity, exacerbates
clinical course of the disease, either relapsing-remitting
(Kwidzinski et al., 2005) or adoptively transferred (Sakurai et al.,
2002). IDO1-deﬁcient mice develop exacerbated acute EAE with
enhanced encephalitogenic Th1 and Th17 cell responses and
reduced Treg cell numbers (Yan et al., 2010). Conversely, adminis-
tration of 3-hydroxyanthranilic acid (3-HAA) (Yan et al., 2010), a
tryptophan catabolite downstream of IDO1 in the kynurenine
pathway, or of an orally active synthetic derivative thereof (Platten
et al., 2005), ameliorates neuroinﬂammation and paralysis in mice
with acute EAE via inhibition of autoreactive Th1/Th17 cells and the
induction of Treg cells. Moreover, cinnabarinic acid (CA), a com-
pound derived from the in vivo spontaneous condensation of two 3-
HAA molecules, also exerts protective effects in acute EAE when
administered continuously commencing on the day of immuniza-
tion with the myelin oligodendrocyte glycoprotein peptide (Fazio
et al., 2014). CA therapeutic effects in vivo are accompanied by an
immune response dominated by Treg cells at the expense of Th17
cells and, in vitro, by TGF-b production from DCs. Of particular in-
terest in the present context, the therapeutic action of CA in acute
EAE associates with the up-regulation of Ido1 and Kynu genes (the
latter coding for kynureninase, an enzyme downstream of IDO1
along the kynurenine pathway that produces 3-HAA) and is
dampened, at least in part, in mice lacking mGluR4 expression
(Fazio et al., 2014). In previous experiments with heterologous
expression systems, CA was indeed shown to act as a selective,
though weak, orthosteric agonist of mGluR4 (Fazio et al., 2012).
Taken together, the available literature points to the possible exis-
tence of an mGluR4-IDO1 loop protecting mice from
neuroinﬂammation.
In our present study, we found that the selective and potent
mGluR4 PAM ADX88178 converted experimental RR-EAE into a
milder form of neuroinﬂammation that remained stable for over
two months after discontinuing drug treatment. In vitro, the drug
appeared to act through mechanisms involving PI3K, Src kinase,
and the signaling activity of IDO1, thus highlighting a major dif-
ference with PHCCC, whose effects on DCs are mediated by a Gi
protein, and thus by the canonical mGluR4 pathway (Conn and Pin,
1997).
The durability of the in vivo therapeutic effects of ADX88178, as
well as the induction of TGF-b production, and the activation of
PI3K and Src kinases in DCs prompted us to further investigate the
IDO1-dependent signaling events. We performed a series of in vitro
and in vivo experiments with DCs and found that ADX88178 and
ADX104608 alone, i.e., in the absence of LPS, signiﬁcantly up-
regulated IDO1 expression and catalytic activity and, perhaps
more importantly, triggered the IDO1 signaling pathway mediated
by phosphorylated IDO1 and noncanonical NF-kB in an mGluR4-
dependent fashion. In contrast, PHCCC was unable to induce
either IDO1 expression and/or signaling under any conditions and
concentrations. Activation of the IDO1 signaling by selective
mGluR4 PAMs was required for TGF-b and IL-10 production and,
more importantly, for in vivo immunosuppression on testing a
diabetogenic autoantigen by in vitro-treated DCs. Because
ADX88178 also upregulated Kynu expression in DCs (Iacono A.,
unpublished observation), our data would suggest that the immu-
noregulatory effects of selective mGluR4 PAMs could be due, at
least in part, to a positive feedback activity of CA, possibly formed
from the condensation of 3-HAA in vitro and/or in vivo, on mGluR4
and thus to the activation of a positive and protective mGluR4-IDO1
loop.
As their name suggests, activation of heterotrimeric G proteins
has normally been considered as the main signaling pathway of
GPCRs. However, a multitude of studies has provided evidence for a
G-proteinindependent signaling occurring in the transduction of
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diversity of GPCRs arises from numerous factors, the most impor-
tant being the ability to adopt multiple (and not merely two, as
previously thought) active states with different effector-coupling
proﬁles (Maudsley et al., 2005). Distinct GPCR ligands, either
orthosteric or allosteric, may thus select a different choice from a
menu of active receptor conformations by virtue of their binding
afﬁnity and efﬁcacy and favor speciﬁc signaling pathways. The
recent obtained crystal structure of mGluR1 bound to a negative
allosteric modulator has unveiled critical residues operating in the
communication between the orthosteric and allosteric site of the
receptor and also directing interaction with other protein partners
(Wu et al., 2014), paving the way to the identiﬁcation of additional
mGluR conformations selected by allosteric ligands. In addition to
the role played by receptor ligands, the cell type may also signiﬁ-
cantly contribute to the choice of signaling pathways by means of a
cell-speciﬁc scaffolding and preorganization of GPCR molecular
partners (Baker and Hill, 2007; Maudsley et al., 2005).
The signaling pathway of mGluR4 has been investigated pri-
marily in heterologous expression systems mostly using nonse-
lective orthosteric agonists (i.e., L-AP-4) and weak PAMs (PHCCC),
with few studies done on nervous and tumor cells. As a whole, the
bulk of observations, including our previous data in DCs stimulated
with LPS and treated with PHCCC (Fallarino et al., 2010), would
point to a Gi-mediated signal transduction (Conn and Pin, 1997;
Tanabe et al., 1993), although alternative pathways mediated by
kinases such as ERK, MAPK, PI3K/Akt, and Src, have also been re-
ported (Iacovelli et al., 2002; Jiang et al., 2006). In general, evidence
for a Gi-mediated signaling can be obtained in the presence of
signals capable of activating adenylyl cyclase either directly (i.e.,
forskolin) or indirectly (Gs-dependent receptors and LPS). As a
matter of fact, PHCCC reduced cAMP levels in DCs, but only in the
presence of forskolin or LPS, and, more importantly, modiﬁed the
DC cytokine proﬁle only in the presence of the TLR4 ligand (as per
our previous (Fallarino et al., 2010) and current data). In contrast,
the in vitro effects of ADX88178 and ADX104608 in DCs, including
TGF-b, IL-10, and IDO1 induction, occurred in the absence of any
additional signal, were PTX-insensitive, and could be inhibited by
PI3K and Src inhibitors. Moreover, the effects were evident at such
low compound concentrations (3 mM) that were insufﬁcient to
inhibit cAMP levels in DCs stimulated with forskolin. Interestingly,
in cerebellar granule cells stimulated in vitro with forskolin, CA
inhibited cAMP formation but only at concentrations30 mM (Fazio
et al., 2012), thus suggesting that alternative signaling pathways
could be still activated at lower concentrations also by CA. Taken
together, our data would suggest that, at least in DCs, different
PAMs may select distinct mGluR4 conformations and thus activate
distinct effector-coupled signaling pathways, further conﬁrming
the great plasticity of mGluRs (Nakanishi, 1994).
5. Conclusions
The discovery of positive allosteric modulators (PAMs) selec-
tively activating distinct mGluRs has clariﬁed that mGluR4 may
represent a promising drug target not only in neuropsychiatric
disorders (Conn et al., 2009) but also in peripheral pathologies such
as chronic inﬂammatory/autoimmune diseases (Celanire and
Campo, 2012; Fallarino et al., 2010; Hansen and Caspi, 2010),
where small-molecule compounds would represent a convenient
alternative to current effective therapies, mainly represented by
expensive biodrugs. ADX88178 and ADX104608, the mGluR4 PAMs
investigated in the current study, are endowed not only with a
pronounced selectivity and high potency, but also with an optimal
pharmacokinetics, good brain-penetrance ability, and almost ab-
sent toxicity (Kalinichev et al., 2014). Taken into consideration thecritical role played by IDO1 in several inﬂammatory/autoimmune
conditions, including rheumatoid arthritis (Seo et al., 2004; Szanto
et al., 2007) and inﬂammatory bowel diseases (Ciorba et al., 2010;
Gurtner et al., 2003; Matteoli et al., 2010) in addition to MS
(Amirkhani et al., 2005; Correale et al., 2009; Fazio et al., 2014;
Kwidzinski et al., 2005; Platten et al., 2005; Sakurai et al., 2002;
Yan et al., 2010; Zhu et al., 2007) and T1D (Fallarino et al., 2009;
Grohmann et al., 2003a; Pallotta et al., 2014), these compounds
may represent the ﬁrst drugs capable of activating the entire
spectrum of functions of such an important target, thus allowing an
efﬁcient resetting of a natural immunoregulatory pathway con-
trolling several immune pathologies.
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